Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia.
1] Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia [2] Melanoma Institute Australia, Sydney, New South Wales, Australia.
Oncogene. 2014 Jan 9;33(2):236-45. doi: 10.1038/onc.2012.562. Epub 2012 Dec 17.
Stimulation of the c-Kit receptor tyrosine kinase has a critical role in the development and migration of melanocytes, and oncogenic c-Kit mutants contribute to the progression of some melanomas. c-Kit signalling activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and their relative contribution to the activities of oncogenic and ligand-dependent c-Kit remains uncertain. We show that PI3K is a major regulator of MAPK activation in response to c-Kit activity and the dominant effector of c-Kit-driven melanocyte proliferation and melanoma survival. Nevertheless, inhibition of the PI3K pathway in c-Kit mutant melanoma cells did not replicate the apoptotic efficacy of the c-Kit inhibitor, imatinib mesylate. Instead, the simultaneous suppression of the PI3K and MAPK pathways promoted a strong synergistic apoptotic effect. These data indicate that MAPK functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Thus, the concurrent inhibition of PI3K and MAPK signalling is required to suppress oncogenic c-Kit activity and may provide an effective therapeutic strategy in c-Kit mutant melanomas.
c-Kit 受体酪氨酸激酶的刺激在黑色素细胞的发育和迁移中起着关键作用,致癌性 c-Kit 突变体有助于一些黑色素瘤的进展。c-Kit 信号激活丝裂原活化蛋白激酶(MAPK)和磷脂酰肌醇 3-激酶(PI3K)途径,但其对致癌和配体依赖性 c-Kit 活性的相对贡献尚不确定。我们表明,PI3K 是 c-Kit 活性诱导的 MAPK 激活的主要调节剂,也是 c-Kit 驱动的黑色素细胞增殖和黑色素瘤存活的主要效应物。然而,在 c-Kit 突变型黑素瘤细胞中抑制 PI3K 途径并没有复制 c-Kit 抑制剂伊马替尼甲磺酸盐的凋亡功效。相反,同时抑制 PI3K 和 MAPK 途径可促进强烈的协同凋亡作用。这些数据表明,MAPK 作为冗余的生存信号,在 c-Kit 突变型黑色素瘤中增强了 PI3K 级联反应。因此,抑制致癌性 c-Kit 活性需要同时抑制 PI3K 和 MAPK 信号,这可能为 c-Kit 突变型黑色素瘤提供有效的治疗策略。